Slides
Page 1
Q2 2026 Financial Results August 6 , 2026 SKINHEALTH SYSTEMS
Page 2
Disclaimer 2 This Pres entation contains certain forward -looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended . These statements may rel ate to, but are not li mited to, expectati ons of future operating res ul ts or financial perform ance of The Beauty Health Company (the "Company"), capital expenditures , the introduction of new products , market strategy and the abi lity to execute certain strategic initiati ves. Some of the forward -looking statements can be identified by the use of forward -looking words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “proj ects ,” “should,” “could,” “would,” “may,” “will,” “outlook,” “forecast” and other sim ilar expressions . These are intended to identify forward -looking statements . All forward -looking statements are bas ed upon management estimates and forecasts and reflect the views, assumptions, expectati ons, and opini ons of the Company as of the date of this Pres entation. Any such estimates, assumptions, expectati ons, forecasts, views or opini ons set forth in this Pres entation constitute the Company’s judgments and shoul d be reg arded as indicative, prel iminary and for illustrative purposes onl y. The forward -looking statements and proj ecti ons contained in this Pres entation are not guarantees of future perform ance, conditions or res ul ts, and are subject to a number of factors, risks and uncertainti es, some of which are not currently known to us, that may cause the Company’s actual res ults, perform ance or financial condition to be materially different from the expectati ons of future res ul ts, perform ance or financial condition . Althoug h such forward -looking statements have been made in good faith and are bas ed on assumptions we believe to be reasonable, there is no assurance that the expected res ults will be achieved . Many factors could adversely affect our business and financial perform ance. We discussed a number of material risks in our Annual Report on Form 10-K for the year ended Decem ber 31, 2025, filed with the Securities and Exchange Commis sion (the “SEC”) on March 12, 2026, and in our subsequent filings with the SEC. Thos e risks continue to be relevant to our perform ance and financial condition . Moreover, we operate in a very com petitive and rapidl y chang ing environm ent. New risk factors emerge from time-to-time and it is not possible for management to predict all such risk factors, nor can it asses s the im pact of all such risk factors on the business or the extent to which any factor, or com bi nation of factors, may cause actual res ul ts to differ materially from those contained in any forward -looking statements . We expressly disclaim any res ponsibili ty to update forward -looking statements, whether as a res ult of new information, future events or otherwise . Non-GAAP Financial Measu res In addition to res ul ts determined in accordance with accounting principles general ly accepted in the United States of America ("GAAP"), management utilizes certain non-GAAP financial meas ures such as adj us ted gross profit, adj us ted gross margin, adj us ted EBITDA, and adj us ted EBITDA margin for purposes of evaluati ng ong oing operations and for internal planning and forecasting purposes . Manag ement believes that these non-GAAP financial meas ures, when reviewed collectively with the Company’s GAAP financial information, provide useful supplemental information to investors in asses sing the Company's operating perform ance. These non-GAAP financial meas ures should not be considered as an alternative to GAAP financial information or as an indication of operating perform ance or any other meas ure of perform ance derived in accordance with GAAP, and may not provide information that is directly com parable to that provided by other com panies in its industry, as these other com panies may calculate non-GAAP financial meas ures differently, particularly related to unus ual items . Adjusted EBITDA is calculated as net loss excluding the effects of expens e (benefit) for income taxes; depreciation expens e; amortizati on expens e; share-bas ed com pensation expens e; interest expens e; interest income ; other income, net; chang e in fair val ue of warrant li abili ti es; foreign currency loss (gain), net; li ti gation rel ated costs; Go-to-Market res tructuring; manufacturing opti mization costs; write-off of discontinued, exces s and obsolete product ; and severance, res tructuring and other. Adjusted EBITDA margin represents adj us ted EBITDA as a percentage of net sales. Adjusted gross profit is gross profit excluding the effects of depreciation expens e, amortizati on expens e, share-bas ed com pensation expens e, manufacturing opti mization costs, write-off of discontinued, exces s and obsol ete product ; and Go-to-Market res tructuring. Adjusted gross margin represents adj us ted gross profit as a percentage of net sales. Adjusted operating expens es is calculated as total operating expens es excluding the effects of depreciation expens e; amortizati on expens e; share-bas ed com pensation expens e; li ti gation rel ated costs ; Go-to-Market res tructuring; transaction rel ated costs ; and severance, res tructuring, and other. The Company does not provide a reconciliation of its fiscal 2026 adj us ted EBITDA guidance to net loss, the most directly com parable forward looking GAAP financial meas ures, due to the inherent diffi culty in forecasting and quantifyi ng certain amounts that are necess ary for such reconciliation, which cannot be done without unreas onabl e efforts, incl udi ng adj us tm ents that could be made for chang es in fair val ue of warrant li abili ti es, integration and acquisition -rel ated expens es, amortizati on expens es, non-cash share-bas ed com pensation, gains/losses on foreign currency, and other charges reflected in our reconciliation of histori c numbers, the amount of which, bas ed on histori cal experience, could be sig nificant. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. The Company's fiscal 2026 adj us ted EBITDA guidance is merely an outlook and is not a guarantee of future perform ance. Stockhol ders shoul d not rel y or place an undue rel iance on such forward -looking statements . See “Forward -Looking Statements” for additional information . This Presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of SkinHealth Systems Inc. (the "Company"), capital expenditures, the introduction of new products, market strategy and the ability to execute certain strategic initiatives. Some of the forward-looking statements can be identified by the use of forward-looking words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “outlook,” “forecast” and other similar expressions. These are intended to identify forward-looking statements. All forward-looking statements are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company as of the date of this Presentation. Any such estimates, assumptions, expectations, forecasts, views or opinions set forth in this Presentation constitute the Company’s judgments and should be regarded as indicative, preliminary and for illustrative purposes only. The forward-looking statements and projections contained in this Presentation are not guarantees of future performance, conditions or results, and are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause the Company’s actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition. Although such forward-looking statements have been made in good faith and are based on assumptions we believe to be reasonable, there is no assurance that the expected results will be achieved. Many factors could adversely affect our business and financial performance. We discussed a number of material risks in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026, and in our subsequent filings with the SEC. Those risks continue to be relevant to our performance and financial condition. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time-to-time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We expressly disclaim any responsibility to update forward-looking statements, whether as a result of new information, future events or otherwise. All material non-public information in this presentation has been simultaneously disclosed in the earnings press release or has otherwise been made public. Non-GAAP Financial Measures In addition to results determined in accordance with accounting principles generally accepted in the United States of America ("GAAP"), management utilizes certain non-GAAP financial measures such as adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EBITDA margin for purposes of evaluating ongoing operations and for internal planning and forecasting purposes. Management believes that these non-GAAP financial measures, when reviewed collectively with the Company’s GAAP financial information, provide useful supplemental information to investors in assessing the Company's operating performance. These non-GAAP financial measures should not be considered as an alternative to GAAP financial information or as an indication of operating performance or any other measure of performance derived in accordance with GAAP, and may not provide information that is directly comparable to that provided by other companies in its industry, as these other companies may calculate non-GAAP financial measures differently, particularly related to unusual items. Adjusted gross profit is gross profit excluding the effects of depreciation expense, amortization expense, share-based compensation expense and other long-term incentive compensation. Adjusted gross margin represents adjusted gross profit as a percentage of net sales. Adjusted operating expenses is calculated as total operating expenses excluding the effects of depreciation expense; amortization expense; share-based compensation expense and other long-term incentive compensation; litigation related costs; Go-to- Market restructuring; and severance, restructuring, and other. Adjusted EBITDA is calculated as net (loss) income excluding the effects of expense (benefit) for income taxes; depreciation expense; amortization expense; share-based compensation expense and other long-term incentive compensation; interest expense; interest income; other income, net; change in fair value of warrant liabilities; foreign currency loss (gain), net; litigation related costs; Go-to-Market restructuring; and severance, restructuring and other. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of net sales. The Company does not provide a reconciliation of its fiscal 2026 adjusted EBITDA guidance to net (loss) income, the most directly comparable forward looking GAAP financial measures, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, which cannot be done without unreasonable efforts, including adjustments that could be made for changes in fair value of warrant liabilities, integration and acquisition-related expenses, amortization expenses, non-cash share-based compensation, gains/losses on foreign currency, and other charges reflected in our reconciliation of historic numbers, the amount of which, based on historical experience, could be significant. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. The Company's fiscal 2026 adjusted EBITDA guidance is merely an outlook and is not a guarantee of future performance. Stockholders should not rely or place an undue reliance on such forward-looking statements. See “Forward-Looking Statements” for additional information.
Page 3
3 This Pres entation contains certain forward -looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended . These statements may rel ate to, but are not li mited to, expectati ons of future operating res ul ts or financial perform ance of The Beauty Health Company (the "Company"), capital expenditures , the introduction of new products , market strategy and the abi lity to execute certain strategic initiati ves. Some of the forward -looking statements can be identified by the use of forward -looking words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “proj ects ,” “should,” “could,” “would,” “may,” “will,” “outlook,” “forecast” and other sim ilar expressions . These are intended to identify forward -looking statements . All forward -looking statements are bas ed upon management estimates and forecasts and reflect the views, assumptions, expectati ons, and opini ons of the Company as of the date of this Pres entation. Any such estimates, assumptions, expectati ons, forecasts, views or opini ons set forth in this Pres entation constitute the Company’s judgments and shoul d be reg arded as indicative, prel iminary and for illustrative purposes onl y. The forward -looking statements and proj ecti ons contained in this Pres entation are not guarantees of future perform ance, conditions or res ul ts, and are subject to a number of factors, risks and uncertainti es, some of which are not currently known to us, that may cause the Company’s actual res ults, perform ance or financial condition to be materially different from the expectati ons of future res ul ts, perform ance or financial condition . Althoug h such forward -looking statements have been made in good faith and are bas ed on assumptions we believe to be reasonable, there is no assurance that the expected res ults will be achieved . Many factors could adversely affect our business and financial perform ance. We discussed a number of material risks in our Annual Report on Form 10-K for the year ended Decem ber 31, 2025, filed with the Securities and Exchange Commis sion (the “SEC”) on March 12, 2026, and in our subsequent filings with the SEC. Thos e risks continue to be relevant to our perform ance and financial condition . Moreover, we operate in a very com petitive and rapidl y chang ing environm ent. New risk factors emerge from time-to-time and it is not possible for management to predict all such risk factors, nor can it asses s the im pact of all such risk factors on the business or the extent to which any factor, or com bi nation of factors, may cause actual res ul ts to differ materially from those contained in any forward -looking statements . We expressly disclaim any res ponsibili ty to update forward -looking statements, whether as a res ult of new information, future events or otherwise . Non-GAAP Financial Measu res In addition to res ul ts determined in accordance with accounting principles general ly accepted in the United States of America ("GAAP"), management utilizes certain non-GAAP financial meas ures such as adj us ted gross profit, adj us ted gross margin, adj us ted EBITDA, and adj us ted EBITDA margin for purposes of evaluati ng ong oing operations and for internal planning and forecasting purposes . Manag ement believes that these non-GAAP financial meas ures, when reviewed collectively with the Company’s GAAP financial information, provide useful supplemental information to investors in asses sing the Company's operating perform ance. These non-GAAP financial meas ures should not be considered as an alternative to GAAP financial information or as an indication of operating perform ance or any other meas ure of perform ance derived in accordance with GAAP, and may not provide information that is directly com parable to that provided by other com panies in its industry, as these other com panies may calculate non-GAAP financial meas ures differently, particularly related to unus ual items . Adjusted EBITDA is calculated as net loss excluding the effects of expens e (benefit) for income taxes; depreciation expens e; amortizati on expens e; share-bas ed com pensation expens e; interest expens e; interest income ; other income, net; chang e in fair val ue of warrant li abili ti es; foreign currency loss (gain), net; li ti gation rel ated costs; Go-to-Market res tructuring; manufacturing opti mization costs; write-off of discontinued, exces s and obsolete product ; and severance, res tructuring and other. Adjusted EBITDA margin represents adj us ted EBITDA as a percentage of net sales. Adjusted gross profit is gross profit excluding the effects of depreciation expens e, amortizati on expens e, share-bas ed com pensation expens e, manufacturing opti mization costs, write-off of discontinued, exces s and obsol ete product ; and Go-to-Market res tructuring. Adjusted gross margin represents adj us ted gross profit as a percentage of net sales. Adjusted operating expens es is calculated as total operating expens es excluding the effects of depreciation expens e; amortizati on expens e; share-bas ed com pensation expens e; li ti gation rel ated costs ; Go-to-Market res tructuring; transaction rel ated costs ; and severance, res tructuring, and other. The Company does not provide a reconciliation of its fiscal 2026 adj us ted EBITDA guidance to net loss, the most directly com parable forward looking GAAP financial meas ures, due to the inherent diffi culty in forecasting and quantifyi ng certain amounts that are necess ary for such reconciliation, which cannot be done without unreas onabl e efforts, incl udi ng adj us tm ents that could be made for chang es in fair val ue of warrant li abili ti es, integration and acquisition -rel ated expens es, amortizati on expens es, non-cash share-bas ed com pensation, gains/losses on foreign currency, and other charges reflected in our reconciliation of histori c numbers, the amount of which, bas ed on histori cal experience, could be sig nificant. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. The Company's fiscal 2026 adj us ted EBITDA guidance is merely an outlook and is not a guarantee of future perform ance. Stockhol ders shoul d not rel y or place an undue rel iance on such forward -looking statements . See “Forward -Looking Statements” for additional information . Strategic Objective Establish SkinHealth Systems as a leader in medical aesthetics, delivering an ecosystem of solutions that uniquely combines devices, consumables, clinical credibility, and brand power to achieve superior skin health for consumers and positive economic outcomes for providers.
Page 4
The Global Medical Aesthetics Market Growing & Increasingly Favorable to SkinHealth Systems 4 Large and addressable global market driven by innovation Clinical credibility and efficacy increasingly drive provider and consumer product choice1 Combination treatments increasing in popularity, driving consumer satisfaction2 Consumer preference shifting toward skin quality treatments2 Skin health is becoming a lifestyle category Broadening consumer demographics – Men, Gen Z, and younger consumers 1. Euromonitor. Voice of the Consumer: Beauty Survey, fielded May 2025. N=20,206. 2. BCG. Medical Aesthetics Provider and Consumer Surveys across ~10,000 respondents; B CG analysis. IMCAS. January 2026
Page 5
Opportunity to leverage our assets to drive profitable growth 5 GROWING GLOBAL FOOTPRINT 36,000+ active devices provide base of cash flow and opportunity to grow ecosystem LOYAL PROVIDERS Valued by providers for attractive economics with equipment payback in as little as 6-9 months2, and ability to bundle with other services COMPELLING BRAND EQUITY IN LARGE, ADDRESSABLE MARKET Hydrafacialis the #2 most recognized brand in aesthetics1 with an accessible price point for consumers and immediately gratifying results HYDRODERMABRASION MARKET LEADER Category strong-hold and omnichannel distribution provides structural advantages ATTRACTIVE ECONOMIC MODEL Profitable unit economics on equipment sales and long-tailed, durable recurring cash flow from consumables sales 1. Ipsos Study 2025. Base: Consumers of the aesthetic and professional beauty category (n=1000); Brand Aided Awareness. 2. Payback calculations and gross annual income based on providing 5-10 Deluxe Hydrafacial treatments a week at SRP of $250 per treatment and working 25 weeks to 50 weeksin the year, respectively.
Page 6
Roadmap to Accelerate Growth 6 PHASE 2 Launch New Products Increasing the Value of the Hydrafacial Device Footprint Expand Into Attractive Adjacent Categories Launching new U.S. device rental program expected in Q3 2026 to make Hydrafacial accessible to more practices. Developing next-generation Hydrafacial device planned for 2028. PHASE 3 AcceleratePHASE 1 Stabilize & Invest in Innovation C U R R E N T L Y E X E C U T I N G P H A S E 1 Strengthening the Core Hydrafacial Franchise Anticipated launch of next clinically validated booster in Q4 2026, with additional innovations planned throughout 2027. Extend SkinStylus microneedling offering. Continue strategic plan to identify, test, and bring a complementary modality device to the U.S. market in 2027. Reposition HydraScalp with Keravive to extend presence into the growing scalp and hair wellness category.
Page 7
Skin Health Benefits Beyond the Face: HydraScalp® with Keravive ¹ NewBeauty Beauty Engine Survey,January 2026(N=1,464) ² Kilmer S, Shamban AT, Callender VD, Jalian HR, Karnik J. Clinical Evaluation of the Effectiveness and Safety of an In-Office Scalp Stimulating Treatment and a Take-HomeScalp Health Product. HydraFacial LLC. 2019 Based on perception of 44 participants receiving a series of 3 Hydrafacial Keravive treatments with daily application of take-home peptide spray in between treatments for 20 weeks. 7 • Advanced, non-invasive scalp treatment with no downtime powered by Hydrafacial’s proprietary Vortex-Fusion Technology Reintroduction of Scalp Health Offering • 73% of consumers are concerned about scalp health and hair growth 1 • 76% of consumers are interested in an in -office treatment that can help with these concerns 1 The Skinification of the Scalp • In a clinical study, 75% of users reported fuller-looking hair, and 82% reported shinier, healthier-looking strands after a series of treatments2 Clinically Proven Results
Page 8
Microneedling with SkinStylus® 1 Guidepoint Qsight - Sales Measurement from Full Year 2025. Qsight Sales Measurement data is based on point-of-sale transactions from 3,400+ US Aesthetics practice locations. 2 Clinical Investigation Report: Evalution of the Efficacy and Safety of the SkinStylus SteriL ock Mircorneedling System for the reatment of facial wrinkles. Rev 4, 2025.N=51 enrolled (50 completed) across 2 U.S. sites. Wrinkle severity assessed using the Lemperle Wrinkle Grading Scale at Baseline, Day 120 and Day 150. 8 • The Only Microneedling Device with Indications for Facial Acne Scars, Periorbital Wrinkles, and Abdominal Scars Adjacent Category with Growth Potential Microneedling is one of the fastest growing categories in medical aesthetics1 Clinically Proven Skin Health Solution SkinStylus reduces the appearance of fine lines and periorbital wrinkles2 Versatile and Flexible Device Microneedling and nano - channeling options to help address a wide range of skin concerns Complementary to Hydrafacial As a standalone treatment or in combination protocols The Only Microneedling Device with Indications for Facial Acne Scars, Periorbital Wrinkles, and Abdominal Scars
Page 9
Corporate Rebrand in Q2 2026 9 "This is not simply a change in name. It represents a fundamental evolution in how we operate, and how we intend to compete. Our focus is on building a durable, scalable ecosystem of skin health technologies and solutions that delivers consistent, provider - led outcomes and creates long -term value for our customers and stakeholders. “ - Pedro Malha, SkinHealth Systems CEO
Page 10
Q2 2026 Financial Highlights and Guidance 10
Page 11
Second Quarter 2026 Financial Highlights 11 Net Sales Delivery Systems Net Sales Consumables Net Sales $17.0m +$3.1m YoY Adjusted EBITDA 1 Net Income (Loss) $72.1m -7.8% YoY $18.3m -18.4% YoY $53.9m -3.5% YoY Increase due to lower adjusted operational spend and higher gross margin, partially offset by lower net sales. Primarily impacted by reduced delivery system placements and lower consumables sales. Decrease in delivery systems net sales, as challenging market conditions persist. Decrease in consumables net sales due to pressure on treatment volume and timing of prior year booster launches. Change primarily due to $18.1 million net gain related to the exchange and repurchases of the 2026 Notes in Q2 2025. $(2.7)m -$22.4m YoY 1. Non-GAAP measure; please refer to the appendix for a reconciliation to the appropriate GAAP measure.
Page 12
Revised 2026 Financial Guidance 12 $65 – $70m 3Q 2026E net sales $5 – $7m 3Q 2026E adjusted EBITDA1 3Q 2026 $280 – $290m FY 2026E net sales $39 – $46m FY 2026E adjusted EBITDA1 FY 2026 1. Adjusted EBITDA is a non-GAAP measure; please refer to the disclaimer for a discussion of the definition of this measure and important information regarding the assumptions underlying the outlook.
Page 13
Appendix: Non-GAAP Financial Reconciliations 13
Page 14
Reconciliation of gross profit to adjusted gross profit 1 Amounts may not sum due to rounding 2 Includes expense associated with long-term cash performance awardsthat can be settled in either cash or Common Stock14 Three Months Ended June 30, Six Months Ended June 30, Unaudited ($ in millions) (1) 2026 2025 2026 2025 Net sales $ 72.1 $ 78.2 $ 137.0 $ 147.8 Gross profit $ 49.3 $ 49.1 $ 93.8 $ 97.7 Gross margin 68.4% 62.8% 68.4% 66.1% Adjusted to exclude the following: Depreciation expense 0.2 0.2 0.4 0.4 Amortization expense 2.1 2.1 4.2 3.1 Share-based compensation expense and other long-term incentive compensation (2) 0.1 0.1 0.2 0.3 Adjusted gross profit $ 51.8 $ 51.5 $ 98.7 $ 101.6 Adjusted gross margin 71.8% 65.9% 72.0% 68.7%
Page 15
Reconciliation of operating expenses to adjusted operating expenses 15 1 Amounts may not sum due to rounding 2 Includes expense associated with long-term cash performance awardsthat can be settled in either cash or Common Stock 3 Includes the proposed settlement in the Securities Class Action suit 4 Includes costs associated with transition to a distributor model in the China and Australia and New Zealand markets Three Months Ended June 30, Six Months Ended June 30, Unaudited ($ in millions) (1) 2026 2025 2026 2025 Total operating expenses $ 45.8 $ 51.8 $ 92.0 $ 112.4 Adjusted to exclude the following: Depreciation expense 0.3 0.5 0.7 2.1 Amortization expense 2.6 2.6 5.3 5.9 Share-based compensation expense and other long-term incentive compensation (2) 2.8 5.2 4.8 8.5 Litigation related costs (3) 4.9 5.0 7.0 11.9 Go-to-Market restructuring (4) (0.2) 0.2 - 3.0 Severance, restructuring and other 0.5 0.6 1.0 0.6 Adjusted operating expenses $ 34.8 $ 37.6 $ 73.1 $ 80.4
Page 16
Reconciliation of net income (loss) to adjusted EBITDA 16 1 Amounts may not sum due to rounding 2 Includes expense associated with long-term cash performance awardsthat can be settled in either cash or Common Stock 3 Includes the proposed settlement in the Securities Class Action suit 4 Includes costs associated with transition to a distributor model in the China and Australia and New Zealand markets Three Months Ended June 30, Six Months Ended June 30, Unaudited ($ in millions) (1) 2026 2025 2026 2025 Net sales $ 72.1 $ 78.2 $ 137.0 $ 147.8 Net (loss) income $ (2.7) $ 19.7 $ (9.3) $ 9.6 Net (loss) income margin (3.7%) 25.2% (6.8%) 6.5% Adjusted to exclude the following: Expense (benefit) for income taxes 1.2 (1.0) 1.0 (0.1) Depreciation expense 0.5 0.7 1.1 2.6 Amortization expense 4.7 4.7 9.5 9.0 Share-based compensation expense and other long-term incentive compensation (2) 3.0 5.3 5.1 8.8 Interest expense 6.3 4.1 12.6 6.6 Interest income (1.3) (3.2) (2.8) (6.2) Other income, net - (18.1) (1.1) (18.2) Change in fair value of warrant liabilities - 0.2 - (0.1) Foreign currency loss (gain), net - (4.5) 1.2 (6.3) Litigation related costs (3) 4.9 5.0 7.0 11.9 Go-to-Market restructuring (4) (0.2) 0.2 - 3.0 Severance, restructuring and other 0.5 0.6 1.0 0.6 Adjusted EBITDA $ 17.0 $ 13.9 $ 25.5 $ 21.2 Adjusted EBITDA margin 23.6% 17.8% 18.6% 14.3%